Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?-Reference-Cited by-同舟云学术

Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?

Published:2014-12-17 Issue:1 Volume:8 Page:29-39
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Menon Devidas,Stafinski Tania,Dunn Andrea,Short Hilary

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40271-014-0106-8.pdf

Reference140 articles.

1. Canadian Drug Expert Committee final recommendation—plain language version: eltrombopag olamine (Revolade-GlaxoSmithKline Inc.). Indication: chronic immune (idiopathic) thrombocytopenic purpura. Common Drug Review (CDR). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2011.

2. CEDAC final recommendation: eculizumab (Soliris-Alexion Pharmaceuticals, Inc.). Indication: paroxysmal noctural hemoglobinuria. Common Drug Review (CDR). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2010.

3. CEDAC final recommendation on reconsideration and reasons for recommendation: pegvisomant (Somavert-Pfizer Canada Inc.). Common Drug Review (CDR). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2006.

4. CEDAC final recommendation: eltrombopag olamine (Revolade-GlaxoSmithKline Inc.). Indication: chronic immune (idiopathic) thrombocytopenic purpura. Common Drug Review (CDR). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2011.

5. CEDAC final recommendation: tocilizumab (Actemra-Hoffmann-La Roche). New indication: arthritis, systemic juvenile idiopathic. Common Drug Review (CDR). Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2012.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient's reporting of adverse drug reactions: Which added value in 2023?;Therapies;2023-10

2. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union;Saudi Pharmaceutical Journal;2023-09

3. Safeguarding NICE from patient groups’ conflicts of interest;BMJ;2023-05-31

4. A cost-of-illness study of Behçet syndrome in Italy;The European Journal of Health Economics;2023-05-22

5. Patient and citizen participation at the organizational level in health technology assessment: an exploratory study in five jurisdictions;International Journal of Technology Assessment in Health Care;2023